NAYA Biosciences has Expanded the Oncology Pipeline with Promising New Antibody
NAYA Biosciences a portfolio company specializing in oncology, autoimmune diseases, and women’s health, has announced its plans to introduce a novel PD-1 x VEGF bifunctional antibody, NY-500, into its growing oncology pipeline.
This new therapeutic candidate is designed to target hepatocellular carcinoma (HCC) and other solid tumors.
The company’s stock has recently seen positive momentum, showing a 10.85% gain over the past week, according to InvestingPro data.
Utilizing its proprietary FLEX antibody platform, NAYA is collaborating with MabSilico, an artificial intelligence and deep technology firm, to accelerate the development of this dual-targeting antibody.
The antibody aims to enhance T-cell infiltration and immune response while disrupting tumor vasculature, with an initial focus on HCC and other solid tumors.
Daniel Teper, President of NAYA Biosciences, expressed confidence in the potential of NY-500, noting that the AI-optimized candidate may demonstrate synergistic activity, which could lead to improved clinical responses.
The antibody is expected to enter phase 1/2a clinical trials in early 2026, following encouraging clinical data from similar PD-1 x VEGF antibodies.
In addition to the new PD-1 x VEGF antibody, NAYA is advancing another promising candidate, NY-303, a GPC3-targeting bifunctional antibody currently in clinical trials for HCC patients who have not responded to existing therapies.
The company’s portfolio also includes NY-338, targeting multiple myeloma and autoimmune diseases, and NY-600, focused on metastatic castration-resistant prostate cancer.
With the PD(L)1 market projected to exceed $50 billion by 2025, according to IQVIA, NAYA’s strategic expansion positions it well for continued growth and success. At a current share price of $0.87, investors can access detailed financial analysis and insights through InvestingPro, which highlights the company’s strong financial health.
In related news, NAYA Biosciences recently completed a merger with INVO Bioscience, uniting INVO’s fertility business with NAYA’s clinical-stage assets. This strategic move is expected to drive innovation and growth, with the combined entity leveraging resources to further expand its oncology and autoimmune disease pipeline.
For more information on NAYA Biosciences’ strategic initiatives and investment opportunities, visit InvestingPro for exclusive metrics and analysis.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023